GEO help: Mouse over screen elements for information.
|Public on Dec 01, 2023
|In vitro throughput screening of anticancer drugs by patient-derived cell lines cultured on vascularized three-dimensional stromal tissues
|Expression profiling by array
|The development of high-throughput anticancer drug screening using patient-derived cancer cell lines (PDCs) that maintain their original characteristics in an in vitro three-dimensional (3D) culture system poses a significant challenge for achieving personalized cancer medicine. Because stromal tissue plays a critical role in the composition and maintenance of the cancer microenvironment, in vitro 3D-culture using reconstructed stromal tissues has attracted much attention. Here, a simple and unique in vitro 3D-culture method using heparin and collagen together with fibroblast and endothelial cells to fabricate vascularized 3D-stromal tissues for in vitro culture of PDCs is reported. While co-treatment with bevacizumab, a monoclonal antibody against the vascular endothelial growth factor, and 5-fluorouracil (5-FU) significantly reduced the survival rate of the 3D-cultured PDCs to 30%, separate addition of each drug did not induce such strong cytotoxicity, suggesting the possibility of evaluating the combined effect of anticancer drug and an angiogenesis inhibitor. Surprisingly, drug evaluation using eight PDCs with the 3D-culture method resulted in a drug efficacy concordance rate of 75% with clinical history. The model is expected to be applied to in vitro throughput drug screening for the development of personalized cancer medicine.
|The gene expression of fibroblast cells in 3D tissue and 2D was measured at 4days after constructing 3D tissue and seeding fibroblast on 10cm dish.
|Takahashi Y, Morimura R, Tsukamoto K, Gomi S, Kato A, Mizukami M, Naito Y, Irie S, Nagayama S, Shinozaki E, Yamaguchi K, Fujita N
|Nov 16, 2023
|Last update date
|Dec 01, 2023
|TOPPAN Holdings Inc.
|Agilent-072363 SurePrint G3 Human GE v3 8x60K Microarray 039494 [Probe Name Version]
|TAR (of TXT)